Health Condition 1: K74- Fibrosis and cirrhosis of liver Health Condition 2: K740- Hepatic fibrosis
Conditions
Interventions
Intervention1: Ascorbic acid: 1. Treatment group-3gm of ascorbic acid diluted in 100 ml of 0.9% saline solution will be administered intravenously during the start of graft implantation and post opera
Sponsors
V M NAVEEN RAJ
Eligibility
Inclusion criteria
Inclusion criteria: Adult living donor liver transplant recipients willing to take part in the study.
Exclusion criteria
Exclusion criteria: 1. Renal dysfunction due to calcinosis. 2. Unresolving HRS. 3. Known Allergy to ascorbic acid 4. Glucose-6-phosphate dehydrogenase (G6PD) deficiency 5. Hyperoxaluria 6. Hyperuricemia 7. Haemochromatosis 8. ABOi transplants
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in the incidence of reperfusion syndrome following adult living donor liver transplantation with Ascorbic acid infusion after the start of graft implantationTimepoint: Intra-operative duration of liver implantation-5 minutes after reperfusion. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Dose of vassopressors during the time of reperfusion 2. Thromboelastogram 3. Blood Products requirement after reperfusion 4. Rates of early graft dysfunction & PNF (Olthoff criteria) 5. Length of ICU & Hospital stay 6. Development of postoperative kidney failure (acute kidney injury [AKI]) during the first week. 7. Time zero biopsy of the graft after reperfusion 8. Proinflammatory cytokines levels after reperfusion (IL-1, IL-2, IL-8 & TNF-a Timepoint: 4 weeks | — |
Countries
India
Contacts
Public ContactDR S SUDHINDRAN
Amrita Institute of medical sciences
Outcome results
None listed